HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

MDL 201053

Subscribe to New Research on MDL 201053

Immunosuppressive Agent; RN given refers to compound with no isomeric designation

Also Known As:

MDL 201053, (R-(R*,S*))-isomer; MDL 201053, (S-(R*,R*))-isomer; MDL 201117; MDL-201053; MDL-201117; Z-FA-FMK; Z-Phe-Ala-CH2F; Z-Phe-Ala-FMK; Z-Phe-AlaCH2F; ZFA-fmk; benzyloxycarbonyl-Phe-Ala-fluormethylketone; benzyloxycarbonylphenylalanyl-alanine fluoromethyl ketone; carbobenzoxy-L-phenylalanyl-(D,L)-alanyl fluoromethyl ketone

Networked: 8 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yanardag, Refiye: 2 articles (05/2010 - 01/2010)
2.	Bayrak, Bertan Boran: 2 articles (05/2010 - 01/2010)
3.	Gezginci-Oktayoglu, Selda: 2 articles (05/2010 - 01/2010)
4.	Bolkent, Sehnaz: 2 articles (05/2010 - 01/2010)
5.	Hansen, Kristina K: 1 article (01/2010)
6.	Lee, Patrick W K: 1 article (01/2010)
7.	Rancourt, Derrick E: 1 article (01/2010)
8.	Fox, Julie D: 1 article (01/2010)
9.	Oztay, Fusun: 1 article (01/2010)
10.	Johnston, Randal N: 1 article (01/2010)

Related Diseases

1.	Infection 01/01/2010 - "The dipeptide benzyloxycarbonyl-Phe-Ala-fluoromethyl ketone (Z-FA-FMK) effectively inhibited reovirus replication in a susceptible host and cured cells of a persistent infection with reovirus in vitro. "
2.	Lung Injury 01/01/2010 - "The present study was designed to investigate the effects of benzyloxicarbonyl-L-phenylalanyl-alanine-fluoromethylketone (Z-FA.FMK), an inhibitor of cathepsin B on lung injury that occurs concurrently with liver injury induced by D-galactosamine/tumor necrosis factor-alpha (D-GalN/TNF-alpha). "
3.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/01/2010 - "Animal studies showed that reovirus infection of Ras oncogenic tumours and host heart tissues is completely blocked by Z-FA-FMK treatment in severe combined immunodeficiency mice. "
4.	Reoviridae Infections 01/01/2010 - "Animal studies showed that reovirus infection of Ras oncogenic tumours and host heart tissues is completely blocked by Z-FA-FMK treatment in severe combined immunodeficiency mice. "
5.	Obstructive Jaundice (Cholestatic Jaundice) 11/01/2009 - "Group 5 (Obstructive jaundice with ZFA-FMK: OBZFA) underwent common bile duct ligation and were simultaneously treated with ZFA-FMK (dissolved in DMSO). "

Related Drugs and Biologics

1.	phenylalanylalanine
2.	Cathepsin B
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Galactosamine
5.	Alanine (L-Alanine)
6.	Caspase 9
7.	Caspase 8 (Caspase-8)
8.	Caspase 3 (Caspase-3)
9.	NF-kappa B (NF-kB)
10.	Dimethyl Sulfoxide (DMSO)

Related Therapies and Procedures

1.	Ligation